A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment
Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J, et al
Record ID 32007000513
English
Authors' objectives:
"To assess the effectiveness and cost-effectiveness of epoetin alfa, epoetin beta and darbepoetin alfa (referred to collectively in this report as epo) in anaemia associated with cancer, especially that attributable to cancer treatment." (from executive summary)
Authors' recommendations:
Epo is effective in improving haematological response and RBCT requirements, and appears to have a positive effect on HRQoL. The incidence of side-effects and effects on survival remains highly uncertain. If there is no impact on survival, it seems highly unlikely that epo would be considered a cost-effective use of healthcare resources.
Authors' methods:
Review
Details
Project Status:
Completed
URL for project:
http://www.hta.ac.uk/1442
Year Published:
2007
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
England, United Kingdom
MeSH Terms
- Hepatitis C
- Interferon-alpha
Contact
Organisation Name:
NIHR Health Technology Assessment programme
Contact Address:
NIHR Journals Library, National Institute for Health and Care Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK
Contact Name:
journals.library@nihr.ac.uk
Contact Email:
journals.library@nihr.ac.uk
Copyright:
2009 Queen's Printer and Controller of HMSO
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.